ChemComm is publishing its 60th volume in 2024. Over the past 60 years, ChemComm has been the RSC’s most cited journal, and one of the most trusted venues for rapid publication of short communications. In our anniversary year, we recognise the important contributions ChemComm has made, and continues to make, in advancing the chemical sciences.
As part of our anniversary celebrations, we’ve brought together a collection featuring the latest research from some of our most loyal and dedicated authors. From those marking the beginning of their independent academic career by publishing their first article with us, to the rising stars and established leaders publishing in our yearly ‘Emerging Investigators’ and ‘Pioneering Investigators’ collections, this collection champions the contributions of our worldwide author community. We are proud many authors choose to support our journal by regularly publishing their best work with us. This collection also features papers from our ChemComm Emerging Investigator Lectureship winners, and our Outstanding Reviewer awardees, whose invaluable feedback has shaped our published content through the years.
To accompany the collection, we’ll be publishing interviews with contributing authors where they provide further insight into their research and reflect on their journey with ChemComm.
Check out our interview with Herman Sintim (Purdue University, USA) below!
 |
Herman O. Sintim obtained his BS from University College London, DPhil from University of Oxford and held postdoctoral positions at Oxford and Stanford Universities before joining the University of Maryland at College Park (UMD) in 2006, where he rose through the ranks to become a full Professor in 2015. From January 2016, Herman has been the Drug Discovery Professor at Purdue University. From 2020 to 2022, Herman served as Program Director at the NSF (Chemistry). In 2023, Herman became the Richard B. Wetherill Distinguished Professor of Chemistry and Drug Discovery at Purdue University. From January 2025, Herman will become the Grace-Rupley Professor of Chemical Biology and Associate Director of Harper Cancer Research Institute at the University of Notre Dame. |
What is your favourite thing about ChemComm?
The time from submission to first online publication is short and the review process is fair.
In what ways do you think ChemComm stands out among other journals in your field?
Published articles are of outstanding quality, articles are concisely written and key points are easy to find and the published articles are also timely.
Could you provide a brief summary of your recent ChemComm publication?
Stimulator of interferon genes (STING) is an important player in immunity and hence has emerged as a potential target for the development of immunomodulatory drugs. Thus far only a handful of STING inhibitors have been reported and none have been shown to have desirable oral bioavailability, which is desired for translation. This work presents one of the early, if not the first (to the best of our knowledge) example of an orally bioavailable STING inhibitor.
In your opinion, what are the next steps or potential areas of research that could build upon the findings in this paper?
With orally bioavailable STING inhibitor now available, scientist can investigate how inhibition of STING in vivo could ameliorate inflammatory pathologies, including organ failure and fibrosis.
Be sure to read Herman’s article, “Orally bioavailable STING antagonist synthesized via multi-component Povarov–Doebner type reaction” to learn more!
